Literature DB >> 6121091

Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy.

W H Burns, R Saral, G W Santos, O L Laskin, P S Lietman, C McLaren, D W Barry.   

Abstract

Sensitivity of herpes simplex virus isolates to acyclovir became reduced in two bone-marrow transplant patients treated for established mucocutaneous infections. These isolates were thymidine-kinase-deficient mutants and were isolated within a week of discontinuation of a 1 week course of acyclovir therapy. The herpetic lesions in both patients continued to heal despite continued shedding of these viruses. Further studies and experience with this new class of antiviral agents are needed to determine the extent to which emergence of less sensitive virus will present clinical difficulties and to formulate treatment regimens that will minimise the emergence of such mutants.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121091     DOI: 10.1016/s0140-6736(82)91620-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  55 in total

Review 1.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  Manzamine A as a novel inhibitor of herpes simplex virus type-1 replication in cultured corneal cells.

Authors:  Jayavardhana R Palem; Gautam R Bedadala; Khalid A El Sayed; Shao-chung V Hsia
Journal:  Planta Med       Date:  2010-07-19       Impact factor: 3.352

3.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

4.  Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir.

Authors:  S Kit; M Sheppard; H Ichimura; S Nusinoff-Lehrman; M N Ellis; J A Fyfe; H Otsuka
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 5.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

6.  Famciclovir for the management of genital herpes simplex in patients with inadequate response to aciclovir or valaciclovir.

Authors:  Stephen L Sacks; Fred Y Aoki
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 7.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 8.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

9.  Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Authors:  M N Ellis; D C Lobe; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 10.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.